RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 12.1426

Change

-0.19 (-1.55)%

Market Cap

N/A

Volume

9.94K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-07 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.18 (-0.41%)

USD 1.42B
PSQ ProShares Short QQQ

-0.15 (-0.39%)

USD 0.67B
SPXU ProShares UltraPro Short S&P50..

-0.26 (-1.13%)

USD 0.52B
SOXS Direxion Daily Semiconductor B..

-0.92 (-5.13%)

USD 0.46B
YANG Direxion Daily FTSE China Bear..

+2.41 (+6.51%)

USD 0.27B
SDOW ProShares UltraPro Short Dow30

-1.05 (-1.99%)

USD 0.23B
RWM ProShares Short Russell2000

-0.06 (-0.29%)

USD 0.21B
FNGD MicroSectors FANG+ Index -3X I..

+0.05 (+0.46%)

USD 0.18B
SPDN Direxion Daily S&P 500® Bear ..

-0.05 (-0.44%)

USD 0.18B
DOG ProShares Short Dow30

-0.19 (-0.69%)

USD 0.14B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.04% 62% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.04% 60% D- 72% C
Trailing 12 Months  
Capital Gain 8.84% 88% B+ 75% C
Dividend Return 2.62% 58% F 49% F
Total Return 11.45% 88% B+ 75% C
Trailing 5 Years  
Capital Gain -56.61% 80% B- 7% C-
Dividend Return 3.13% 74% C 6% D-
Total Return -53.49% 80% B- 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 66.86% 39% F 96% N/A
Dividend Return 68.32% 39% F 96% N/A
Total Return 1.47% 60% D- 35% F
Risk Return Profile  
Volatility (Standard Deviation) 432.96% 63% D 3% F
Risk Adjusted Return 15.78% 52% F 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.